Program
GENSCI134
A development code. Also written as “GenSci134 Injection” and “GenSci134”.
Its studies are mostly in Dwarfism, Pituitary, led by Changchun GeneScience Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 33 open or running | phase 2since Feb 12, 2026 | May 30, 2025 | Nov 25, 2026phase 1 · NCT07016802 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 30, 2025First study: phase 1 study in Dwarfism, PituitaryFirst studyNCT07016802 · 64 planned · China
- Feb 12, 20262 phase 2 studiesPhase 2 reachedNCT07450053, NCT07450001
Ahead
- Nov 25, 2026Primary completion: phase 1 study in Dwarfism, PituitaryNCT07016802
- Jul 18, 2028Primary completion: phase 2 study in Idiopathic Short StatureNCT07450053
- Jul 18, 2028Primary completion: phase 2 study in Pediatric Growth Hormone DeficiencyNCT07450001
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07450053Idiopathic Short Stature · China | 2 | Not yet recruiting | Jul 18, 2028 | 128 |
| NCT07450001Pediatric Growth Hormone Deficiency · China | 2 | Not yet recruiting | Jul 18, 2028 | 128 |
| NCT07016802Dwarfism, Pituitary · China | 1 | Recruiting | Nov 25, 2026 | 64 |
How it is read
Names in the registry
- “GenSci134 Injection”, 2 entries
- “GenSci134”, 1 entry
Codes read as this program: GENSCI134.
Conditions, from the studies’ own filings
- Dwarfism, Pituitary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.